Kips Bay Medical has enrolled first patients for its European eSVS Mesh post-market study at the University Hospital Kiel.
The prospective controlled, multi-center, randomized clinical study, enrolling patients up to 200, is designed to assess the short and long-term patency of saphenous vein grafts treated with the eSVS Mesh during coronary artery bypass surgery.
Patency will be evaluated at 6 months and 2 years post implant.
The company said data from these studies will be used to further support the marketing of and reimbursement requirements for the eSVS MESH internationally.